Header Logo

Connection

NAOTO T UENO to Receptor, ErbB-2

Back to Details
This is a "connection" page, showing publications NAOTO T UENO has written about Receptor, ErbB-2.
NAOTO T UENO
Connection Strength
5.915
Receptor, ErbB-2
  1. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
    View in: PubMed
    Score: 0.344
  2. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
    View in: PubMed
    Score: 0.324
  3. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017 Oct 01; 28(10):2420-2428.
    View in: PubMed
    Score: 0.308
  4. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014 Jul; 146(2):259-72.
    View in: PubMed
    Score: 0.245
  5. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol. 2014 Feb; 25(2):384-91.
    View in: PubMed
    Score: 0.237
  6. Fuel, electricity, ER and HER2--a hybrid-car model of breast cancer. Nat Rev Clin Oncol. 2012 Jun 05; 9(7).
    View in: PubMed
    Score: 0.213
  7. Change in HER2 status during breast tumor progression. Cancer Biomark. 2012-2013; 12(6):251-5.
    View in: PubMed
    Score: 0.206
  8. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012 Feb 20; 30(6):593-9.
    View in: PubMed
    Score: 0.205
  9. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist. 2011; 16(7):956-65.
    View in: PubMed
    Score: 0.199
  10. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol. 2012 Apr; 17(2):96-104.
    View in: PubMed
    Score: 0.199
  11. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int J Clin Oncol. 2012 Feb; 17(1):55-62.
    View in: PubMed
    Score: 0.198
  12. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. Int J Clin Oncol. 2011 Oct; 16(5):596-600.
    View in: PubMed
    Score: 0.193
  13. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2008 Jul; 7(7):1846-50.
    View in: PubMed
    Score: 0.162
  14. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15; 65(18):8406-13.
    View in: PubMed
    Score: 0.133
  15. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 07 07; 387(1):9-20.
    View in: PubMed
    Score: 0.106
  16. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021 Sep; 189(2):455-461.
    View in: PubMed
    Score: 0.099
  17. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021 06 10; 12(1):3528.
    View in: PubMed
    Score: 0.099
  18. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One. 2021; 16(4):e0250057.
    View in: PubMed
    Score: 0.098
  19. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Bioorg Med Chem. 2021 02 15; 32:116013.
    View in: PubMed
    Score: 0.096
  20. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res. 2021 03; 29:1-12.
    View in: PubMed
    Score: 0.094
  21. The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Breast Cancer Res Treat. 2020 Oct; 183(3):729-739.
    View in: PubMed
    Score: 0.093
  22. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist. 2020 06; 25(6):e909-e919.
    View in: PubMed
    Score: 0.090
  23. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9.
    View in: PubMed
    Score: 0.090
  24. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol. 2000; 465:171-80.
    View in: PubMed
    Score: 0.090
  25. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncol Rep. 1999 Mar-Apr; 6(2):257-62.
    View in: PubMed
    Score: 0.085
  26. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat. 2019 Jan; 173(1):1-9.
    View in: PubMed
    Score: 0.082
  27. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.082
  28. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
    View in: PubMed
    Score: 0.079
  29. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One. 2017; 12(9):e0185231.
    View in: PubMed
    Score: 0.077
  30. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017 Sep 01; 3(9):1266-1273.
    View in: PubMed
    Score: 0.076
  31. Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''. Br J Cancer. 2017 04 11; 116(8):e11.
    View in: PubMed
    Score: 0.074
  32. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(2):263-272.
    View in: PubMed
    Score: 0.074
  33. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer. 2017 Feb 14; 116(4):509-514.
    View in: PubMed
    Score: 0.073
  34. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016 Sep; 159(2):367-74.
    View in: PubMed
    Score: 0.071
  35. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist. 2016 Jan; 21(1):21-7.
    View in: PubMed
    Score: 0.068
  36. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7.
    View in: PubMed
    Score: 0.065
  37. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One. 2014; 9(1):e83113.
    View in: PubMed
    Score: 0.059
  38. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res. 2013 Sep 01; 19(17):4685-96.
    View in: PubMed
    Score: 0.056
  39. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):523-31.
    View in: PubMed
    Score: 0.055
  40. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):331-45.
    View in: PubMed
    Score: 0.055
  41. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012 Nov; 11(11):2526-34.
    View in: PubMed
    Score: 0.054
  42. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8.
    View in: PubMed
    Score: 0.047
  43. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007 Aug; 6(8):2168-77.
    View in: PubMed
    Score: 0.038
  44. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther. 2007 Jan; 6(1):227-35.
    View in: PubMed
    Score: 0.037
  45. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene. 2006 Jan 05; 25(1):79-90.
    View in: PubMed
    Score: 0.034
  46. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release. 2004 Jun 18; 97(2):357-69.
    View in: PubMed
    Score: 0.031
  47. Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer. Breast Cancer Res Treat. 2024 Apr; 204(2):289-297.
    View in: PubMed
    Score: 0.030
  48. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res. 2001 Dec; 7(12):4008-12.
    View in: PubMed
    Score: 0.026
  49. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274.
    View in: PubMed
    Score: 0.024
  50. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Ann Surg Oncol. 2020 Nov; 27(12):4603-4612.
    View in: PubMed
    Score: 0.023
  51. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430.
    View in: PubMed
    Score: 0.023
  52. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol. 2020 09; 46(9):1588-1595.
    View in: PubMed
    Score: 0.023
  53. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. Mol Oncol. 2020 03; 14(3):504-519.
    View in: PubMed
    Score: 0.023
  54. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351.
    View in: PubMed
    Score: 0.021
  55. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Ann Surg Oncol. 2017 Oct; 24(10):2981-2988.
    View in: PubMed
    Score: 0.019
  56. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer. 2017 Jul 01; 123(13):2422-2431.
    View in: PubMed
    Score: 0.018
  57. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors. PLoS One. 2017; 12(1):e0170081.
    View in: PubMed
    Score: 0.018
  58. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. J Natl Cancer Inst. 2016 08; 108(8).
    View in: PubMed
    Score: 0.017
  59. The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. PLoS One. 2016; 11(4):e0152585.
    View in: PubMed
    Score: 0.017
  60. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar; 27(3):359-66.
    View in: PubMed
    Score: 0.017
  61. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
    View in: PubMed
    Score: 0.017
  62. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol. 2014 Feb; 25(2):358-65.
    View in: PubMed
    Score: 0.015
  63. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. Clin Breast Cancer. 2013 Dec; 13(6):460-4.
    View in: PubMed
    Score: 0.015
  64. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(3):761-72.
    View in: PubMed
    Score: 0.014
  65. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer. 2012 Mar 13; 106(6):1107-16.
    View in: PubMed
    Score: 0.013
  66. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 2012 May; 23(5):1144-1150.
    View in: PubMed
    Score: 0.013
  67. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist. 2011; 16(2):155-64.
    View in: PubMed
    Score: 0.012
  68. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011 Mar; 22(3):515-523.
    View in: PubMed
    Score: 0.012
  69. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J. 2010 May-Jun; 16(3):327-30.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.